Cargando…

Levetiracetam Rectal Administration in Healthy Dogs

BACKGROUND: Levetiracetam is used to manage status epilepticus (SE) and cluster seizures (CS) in humans. The drug might be absorbed after rectal administration and could offer a practical adjunct to rectal administration of diazepam in managing SE and CS. HYPOTHESIS: Levetiracetam is rapidly absorbe...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, R.K., Schubert, T., Clemmons, R., Vickroy, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857990/
https://www.ncbi.nlm.nih.gov/pubmed/24417468
http://dx.doi.org/10.1111/jvim.12269
_version_ 1782430727910981632
author Peters, R.K.
Schubert, T.
Clemmons, R.
Vickroy, T.
author_facet Peters, R.K.
Schubert, T.
Clemmons, R.
Vickroy, T.
author_sort Peters, R.K.
collection PubMed
description BACKGROUND: Levetiracetam is used to manage status epilepticus (SE) and cluster seizures (CS) in humans. The drug might be absorbed after rectal administration and could offer a practical adjunct to rectal administration of diazepam in managing SE and CS. HYPOTHESIS: Levetiracetam is rapidly absorbed after rectal administration in dogs and maintains target serum concentrations for at least 9 hours. ANIMALS: Six healthy privately owned dogs between 2 and 6 years of age and weighing 10–20 kg. METHODS: Levetiracetam (40 mg/kg) was administered rectally and blood samples were obtained immediately before (time zero) and at 10, 20, 40, 60, 90, 180, 360, and 540 minutes after drug administration. Dogs were observed for signs of adverse effects over a 24‐hour period after drug administration. RESULTS: C (LEV) at 10 minutes was 15.3 ± 5.5 μg/mL (mean, SD) with concentrations in the target range (5–40 μg/mL) for all dogs throughout the sampling period. C (max) (36.0 ± 10.7 μg/mL) and T (max) (103 ± 31 minutes) values were calculated and 2 disparate groups were appreciated. Dogs with feces in the rectum at the time of drug administration had lower mean C (max) values (26.7 ± 3.4 μg/mL) compared with those without (45.2 ± 4.4 μg/mL). Mild sedation was observed between 60 and 90 minutes without other adverse effects noted. CONCLUSIONS AND CLINICAL IMPORTANCE: This study supports the use of rectally administered levetiracetam in future studies of clinical effectiveness in the management of epileptic dogs.
format Online
Article
Text
id pubmed-4857990
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-48579902016-06-22 Levetiracetam Rectal Administration in Healthy Dogs Peters, R.K. Schubert, T. Clemmons, R. Vickroy, T. J Vet Intern Med Standard Articles BACKGROUND: Levetiracetam is used to manage status epilepticus (SE) and cluster seizures (CS) in humans. The drug might be absorbed after rectal administration and could offer a practical adjunct to rectal administration of diazepam in managing SE and CS. HYPOTHESIS: Levetiracetam is rapidly absorbed after rectal administration in dogs and maintains target serum concentrations for at least 9 hours. ANIMALS: Six healthy privately owned dogs between 2 and 6 years of age and weighing 10–20 kg. METHODS: Levetiracetam (40 mg/kg) was administered rectally and blood samples were obtained immediately before (time zero) and at 10, 20, 40, 60, 90, 180, 360, and 540 minutes after drug administration. Dogs were observed for signs of adverse effects over a 24‐hour period after drug administration. RESULTS: C (LEV) at 10 minutes was 15.3 ± 5.5 μg/mL (mean, SD) with concentrations in the target range (5–40 μg/mL) for all dogs throughout the sampling period. C (max) (36.0 ± 10.7 μg/mL) and T (max) (103 ± 31 minutes) values were calculated and 2 disparate groups were appreciated. Dogs with feces in the rectum at the time of drug administration had lower mean C (max) values (26.7 ± 3.4 μg/mL) compared with those without (45.2 ± 4.4 μg/mL). Mild sedation was observed between 60 and 90 minutes without other adverse effects noted. CONCLUSIONS AND CLINICAL IMPORTANCE: This study supports the use of rectally administered levetiracetam in future studies of clinical effectiveness in the management of epileptic dogs. John Wiley and Sons Inc. 2014-01-13 2014 /pmc/articles/PMC4857990/ /pubmed/24417468 http://dx.doi.org/10.1111/jvim.12269 Text en Copyright © 2014 by the American College of Veterinary Internal Medicine
spellingShingle Standard Articles
Peters, R.K.
Schubert, T.
Clemmons, R.
Vickroy, T.
Levetiracetam Rectal Administration in Healthy Dogs
title Levetiracetam Rectal Administration in Healthy Dogs
title_full Levetiracetam Rectal Administration in Healthy Dogs
title_fullStr Levetiracetam Rectal Administration in Healthy Dogs
title_full_unstemmed Levetiracetam Rectal Administration in Healthy Dogs
title_short Levetiracetam Rectal Administration in Healthy Dogs
title_sort levetiracetam rectal administration in healthy dogs
topic Standard Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857990/
https://www.ncbi.nlm.nih.gov/pubmed/24417468
http://dx.doi.org/10.1111/jvim.12269
work_keys_str_mv AT petersrk levetiracetamrectaladministrationinhealthydogs
AT schubertt levetiracetamrectaladministrationinhealthydogs
AT clemmonsr levetiracetamrectaladministrationinhealthydogs
AT vickroyt levetiracetamrectaladministrationinhealthydogs